Article Sidebar

pdf
Date Published: 19/09/2025
Abstract Views: 87
Views pdf: 58
DOI: https://doi.org/10.51298/vmj.v553i3.15446
Issue
Vol. 553 No. 3 (2025)
Section
Các bài báo
How to Cite
Nguyễn, T. P., Tạ, B. T., & Đào, N. B. (2025). RELATIONSHIP BETWEEN PLASMA MATRIX METALLOPROTEINASE 1, 2, 9, 12 CONCENTRATIONS WITH SOME CLINICAL AND PARACLINICAL CHARACTERISTICS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AFTER ACUTE EXACERBATION. Vietnam Medical Journal, 553(3). https://doi.org/10.51298/vmj.v553i3.15446

RELATIONSHIP BETWEEN PLASMA MATRIX METALLOPROTEINASE 1, 2, 9, 12 CONCENTRATIONS WITH SOME CLINICAL AND PARACLINICAL CHARACTERISTICS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AFTER ACUTE EXACERBATION

Thành Phương Nguyễn, Bá Thắng Tạ, Ngọc Bằng Đào

Main Article Content

Abstract

Objectives: To determine the relationship between plasma Matrix Metalloproteinase (MMP) 1, 2, 9, 12 concentration with some clinical and paraclinical characteristics in patients with chronic obstructive pulmonary disease after acute exacerbation. Subjects and methods: A Cross-sectional study on 65 COPD patients after acute exacerbation treated at the Respiratory Medicine Center - Military Hospital 103 and 33 normal people. Quantification of MMP-1, 2, 9, 12  concentration in plasma by ELISA technique. Results: Plasma MMP-9 concentrations in COPD patients after acute exacerbation are higher than in normal people (p < 0.05). MMP-12 concentrations in COPD patients with group E were lower than in groups A and B (p < 0.05). No association was found between MMP-1, 2, 9, 12  concentrations with smoking characteristics and time of disease duration in COPD patients after acute exacerbation (p > 0.05). Conclusions: Plasma MMP-9 concentrations in COPD patients after an exacerbation are higher than in normal people. Plasma MMP-12 concentrations in patients with group E were lower than those in groups A and B.

Article Details

Keywords

Chronic obstructive pulmonary disease after actue exacerbation; Plasma MMPs concentrations.

References

Christopoulou M-E., Papakonstantinou E., Stolz D. (2023), "Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease", Int J Mol Sci. 14;24(4):3786.
2. Kang M. J., Oh Y. M., Lee J.C., et al. (2003), "Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow", J Korean Med Sci, 18(6): 821-7.
3. Linder R., Rönmark E., Pourazar J., et al. (2015), "Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study", Respir Res, 16(1): 28.
4. The Global Initiative for Chronic Obstructive Lung Disease (2023), Global stragery for prevention, diagnosis and management of COPD: 2023 Report.
5. Phan Thanh Thuỷ, Vũ Văn Giáp, Lê Thị Tuyết Lan, và cộng sự (2022), Đặc điểm lâm sàng và tỷ lệ đợt cấp bệnh phổi tắc nghẽn mạn tính của người bệnh tại một số đơn vị quản lý ngoại trú, Tạp chí nghiên cứu y học, 160 (12V1): 242-250.
6. Mahor D., Kumari V., Vashisht K., et al. (2020), "Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD", BMC Pulm Med, 20(1): 302.
7. Koo H., Hong Y., Lim M.N., et al. (2016), "Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity", International Journal of Chronic Obstructive Pulmonary Disease, 11(1): 1129-1137
8. Russell R. E., Culpitt S.V., DeMatos C., et al. (2002), "Release and activity of matrix metalloproteinase-11 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease", Am J Respir Cell Mol Biol, 26(5): 602-9.